GlaxoSmithKline PLC said Thursday that preclinical data indicate that sotrovimab antibodies retain their efficacy against the key mutations found in the omicron coronavirus mutant.
To date, sotrovimab has been tested for all concerns and concerns defined by the World Health Organization, a British pharmaceutical major said the data was created through pseudoviral testing of the specific individual mutations found in the variant. Showed sustained activity for the variant.
The company said it is currently completing an in vitro pseudoviral test to confirm that sotrovimab can neutralize all combinations of Omicron mutations and will provide the latest information by the end of 2021.
According to GlazoSmithKline, the antibody was designed using Vir Biotechnology Inc. with mutant viruses in mind, targeting highly conserved regions of peaplomers that are unlikely to mutate. Hope to deal with both coronavirus and future mutants.
This antibody has been approved for emergency use in the United States and has received positive feedback from EU agencies. It is also available in other global markets such as the United Kingdom, Japan, Australia, Canada, Singapore and the United Arab Emirates.
“Although in the early stages, these preclinical data support our long-standing view of the potential for sotrovimab to maintain its activity as the virus continues to mutate,” said Chief Scientific Officer. Said Hal Baron.
Write to Joe Hoppe at firstname.lastname@example.org
GlaxoSmithKline states that sotrovimab antibody retains activity against Omicron
Source link GlaxoSmithKline states that sotrovimab antibody retains activity against Omicron
The post GlaxoSmithKline states that sotrovimab antibody retains activity against Omicron appeared first on Eminetra.